Trials / Completed
CompletedNCT01768338
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Michael John Robertson · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ofatumumab combined with SB-485232 | Ofatumumab with escalating doses of SB-485232 |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2016-03-01
- Completion
- 2017-08-03
- First posted
- 2013-01-15
- Last updated
- 2023-02-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01768338. Inclusion in this directory is not an endorsement.